These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 20965606

  • 1. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
    Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ.
    Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
    [Abstract] [Full Text] [Related]

  • 2. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
    Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ.
    Immunobiology; 2011 May; 216(1-2):173-83. PubMed ID: 20598772
    [Abstract] [Full Text] [Related]

  • 3. Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis.
    Campbell AM, Zagon IS, McLaughlin PJ.
    Brain Res Bull; 2013 Jan; 90():43-51. PubMed ID: 22985690
    [Abstract] [Full Text] [Related]

  • 4. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
    McLaughlin PJ, Zagon IS.
    Biochem Pharmacol; 2012 Sep 15; 84(6):746-55. PubMed ID: 22687282
    [Abstract] [Full Text] [Related]

  • 5. Regulation of cell proliferation by the opioid growth factor receptor is dependent on karyopherin beta and Ran for nucleocytoplasmic trafficking.
    Cheng F, McLaughlin PJ, Zagon IS.
    Exp Biol Med (Maywood); 2010 Sep 15; 235(9):1093-101. PubMed ID: 20705629
    [Abstract] [Full Text] [Related]

  • 6. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis.
    Zagon IS, Rahn KA, Bonneau RH, Turel AP, McLaughlin PJ.
    Brain Res; 2010 Jan 15; 1310():154-61. PubMed ID: 19931226
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium.
    Zagon IS, Ruth TB, McLaughlin PJ.
    Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan 15; 282(1):24-37. PubMed ID: 15584033
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
    Zagon IS, McLaughlin PJ.
    Int J Oncol; 2004 Jun 15; 24(6):1443-8. PubMed ID: 15138586
    [Abstract] [Full Text] [Related]

  • 12. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
    Immonen JA, Zagon IS, McLaughlin PJ.
    Exp Biol Med (Maywood); 2014 Oct 15; 239(10):1300-9. PubMed ID: 25030485
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers.
    Zagon IS, McLaughlin PJ.
    Int J Oncol; 2006 Aug 15; 29(2):489-94. PubMed ID: 16820893
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
    Donahue RN, McLaughlin PJ, Zagon IS.
    Gynecol Oncol; 2011 Aug 15; 122(2):382-8. PubMed ID: 21531450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.